Bempedoic Acid

Bempedoic acid is an oral lipid-lowering medication used to reduce low-density lipoprotein (LDL) cholesterol, the form of cholesterol most strongly linked to heart disease. It is the first drug in its class, working by inhibiting an enzyme called ATP-citrate lyase that sits early in the body's cholesterol-manufacturing pathway ^[2]. It is marketed as a single agent under the brand names Nexletol in the United States and Nilemdo in Europe, and in fixed-dose combination with ezetimibe as Nexlizet or Nustendi ^[1].

A defining feature of bempedoic acid is that it is a prodrug, inactive until it is converted to its working form, bempedoyl-CoA, by an activating enzyme found in the liver but essentially absent from skeletal muscle ^[2]. Because the drug is switched on in the liver but not in muscle, it lowers cholesterol production where it matters while largely avoiding the muscle aches and weakness that lead some people to stop taking statins ^[1][2]. Its target enzyme, ATP-citrate lyase, acts upstream of HMG-CoA reductase, the enzyme that statins block, so the two drug classes reduce cholesterol synthesis at different steps of the same pathway ^[2].

Bempedoic acid is used to lower LDL cholesterol in adults who need further reduction beyond diet and other therapy, including people with an inherited cholesterol disorder called heterozygous familial hypercholesterolemia and those with established cardiovascular disease, and it is especially relevant for patients who are intolerant of statins ^[1]. Its clinical value was reinforced by the large CLEAR Outcomes trial, which enrolled statin-intolerant patients and found that bempedoic acid not only reduced LDL cholesterol but also lowered the risk of major adverse cardiovascular events such as heart attack compared with placebo ^[1]. Earlier trials established that it lowers LDL further when added to ezetimibe or to background statin therapy, and comparative analyses have placed its LDL-lowering effect among the useful non-statin options ^[3][4][5].

The drug was approved by the U.S. Food and Drug Administration in February 2020 and by the European Medicines Agency shortly afterward, as an oral tablet ^[1]. It is generally well tolerated, but it carries some characteristic risks: it can raise blood levels of uric acid and precipitate gout, and it has been associated with an increased chance of tendon rupture; muscle spasms and elevations in liver enzymes and creatinine have also been reported ^[1]. These considerations shape how and in whom the drug is prescribed ^[1].

Bempedoic acid is prescription only and is generally well tolerated, with notably less muscle pain than statins. Its more distinctive effects are a rise in uric acid that can set off gout, elevated liver enzymes, a small rise in creatinine, and a signal for tendon injury, especially in older patients or those also taking steroids or fluoroquinolones. It raises blood levels of simvastatin and pravastatin, so those statin doses must be capped when the drugs are combined. It should not be used in pregnancy or while breastfeeding, and uric acid is worth watching in anyone prone to gout.

Bempedoic acid inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, and that raises the blood levels of statins that depend on them. Simvastatin exposure roughly doubles and pravastatin exposure roughly doubles as well, and more statin in the circulation rather than in the liver means a higher risk of myopathy and, rarely, rhabdomyolysis. The effect is large enough that labeling caps how much simvastatin or pravastatin can be given alongside it. Atorvastatin and rosuvastatin rise more modestly.

Bempedoic acid also raises serum uric acid by competing with urate for renal tubular transport, so it can work against urate lowering therapy and precipitate gout in people already prone to it.

Beyond transporters there is little to report. Bempedoic acid is a prodrug activated by ACSVL1, an enzyme present in liver but not skeletal muscle, and it is not a meaningful substrate, inhibitor or inducer of the cytochrome P450 enzymes.

Checking a whole stack? Run it through interactions + stacks.

Bempedoic acid was developed by the American biopharmaceutical company Esperion Therapeutics, which was founded by Roger Newton, a co-discoverer of the statin atorvastatin, giving the program deep roots in cholesterol science. The molecule emerged from research into ATP-citrate lyase as a target upstream of the enzyme that statins block, and its liver-selective activation was designed specifically to avoid the muscle side effects that limit statin use. After a series of trials under the CLEAR program, it received United States FDA approval in February 2020 under the brand name Nexletol, with the European approval as Nilemdo following the same year. In 2023 the large CLEAR Outcomes trial confirmed that it reduces the risk of major cardiovascular events in statin-intolerant patients, cementing its clinical role.

Bempedoic acid has been welcomed as one of the most significant non-statin advances in cholesterol management in years, offering a genuinely new mechanism for a field long dominated by statins. It is especially valued for patients who cannot tolerate statins because of muscle symptoms, since its activation only in the liver largely spares muscle tissue. The credibility of the drug was strengthened when the CLEAR Outcomes trial showed it lowers cardiovascular event rates rather than merely improving a laboratory number, the standard of evidence cardiologists most respect. Physicians do note its tendency to raise uric acid and occasionally trigger gout, and they position it as a useful complement to, rather than a wholesale replacement for, established therapies.